TY - JOUR
T1 - Liquid-Biopsy Glycan Score Biomarker Accurately Indicates and Stratifies Primary and Metastatic Prostate Cancers
AU - Díaz-Fernández, Ana
AU - Ryø Jochumsen, Mads
AU - Christensen, Nana Louise
AU - Dalsgaard Sørensen, Karina
AU - Bouchelouche, Kirsten
AU - Borre, Michael
AU - Holm Vendelbo, Mikkel
AU - Ferapontova, Elena E.
N1 - Publisher Copyright:
© 2024 American Chemical Society.
PY - 2024/11/26
Y1 - 2024/11/26
N2 - Prostate cancer (PCa) is the most commonly diagnosed cancer in males. Early PCa usually shows no clinical symptoms and its primary diagnosis is currently guided by liquid-biopsy testing of serum prostate-specific antigen (PSA). This testing suffers from high false-positive and false-negative rates. Identifying new biomarkers for precise liquid-biopsy detection of PCa is, thus, an acute clinical request. Here, by using an advanced dual-functional aptamer assay, we quantified the extent of glycosylation of PSA circulating in cancer patients’ serum, linked it to cancer-related breakage of PSA complexes with serum-circulating proteins, and proved its facility for stratification of primary and metastatic PCa. PSA’s “Glycan Score” 100% accurately informed about PCa status in a 30-patient cohort, while serum PSA’s concentration correctly classified only 53% of PCa patients and did not inform about their PCa status. The Glycan Score liquid-biopsy test thus has a huge potential for accurate diagnosis and staging of PCa, enabling mass-screening program progress and advanced PCa treatment monitoring.
AB - Prostate cancer (PCa) is the most commonly diagnosed cancer in males. Early PCa usually shows no clinical symptoms and its primary diagnosis is currently guided by liquid-biopsy testing of serum prostate-specific antigen (PSA). This testing suffers from high false-positive and false-negative rates. Identifying new biomarkers for precise liquid-biopsy detection of PCa is, thus, an acute clinical request. Here, by using an advanced dual-functional aptamer assay, we quantified the extent of glycosylation of PSA circulating in cancer patients’ serum, linked it to cancer-related breakage of PSA complexes with serum-circulating proteins, and proved its facility for stratification of primary and metastatic PCa. PSA’s “Glycan Score” 100% accurately informed about PCa status in a 30-patient cohort, while serum PSA’s concentration correctly classified only 53% of PCa patients and did not inform about their PCa status. The Glycan Score liquid-biopsy test thus has a huge potential for accurate diagnosis and staging of PCa, enabling mass-screening program progress and advanced PCa treatment monitoring.
U2 - 10.1021/acs.analchem.4c04316
DO - 10.1021/acs.analchem.4c04316
M3 - Journal article
C2 - 39535906
AN - SCOPUS:85209234537
SN - 0003-2700
VL - 96
SP - 18815
EP - 18823
JO - Analytical Chemistry
JF - Analytical Chemistry
IS - 47
ER -